RUA Life Sciences Sees Strong Revenue Growth and Strategic Momentum

 

RUA Life Sciences plc (LSE:RUA) has reported a robust 86% increase in annual revenue, reaching £4.1 million for the fiscal year ending 31 March 2025. This surge is attributed to solid core business performance and the successful acquisition of Abiss Group. The company also improved its financial position with tighter cost control and better cash management, projecting an EBITDA of £0.3 million—a substantial improvement from last year’s loss.

RUA is doubling down on the expansion of its contract manufacturing division and is actively exploring new licensing opportunities for its proprietary polymer technology, Elast-Eon, particularly in combination with its expertise in medical textiles. Although the Abiss acquisition initially faced slower order volumes due to high customer inventory, RUA expects structural market changes to drive long-term growth in that segment.

About RUA Life Sciences plc
RUA Life Sciences is a medical technology company specializing in long-term implantable devices and materials. It leverages its proprietary Elast-Eon polymer—renowned for its biostability—for medical applications through licensing, contract manufacturing, and in-house product development. The company is positioning itself at the intersection of innovation and scalability in the healthcare sector.

• Year-to-Date Share Performance: +12.50%

• Average Daily Trading Volume: 123,131 shares

• Technical Sentiment: Bullish (Buy Signal)

• Market Capitalization: £7.14 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Kenneth G. Mondero

• 

  Ella Mason

• 

  Lou Gutheil

• 

  Lee Wild